Sigrid Skånland’s project group Functional precision medicine for haematologic cancers
There is an unmet need to tailor cancer therapy to each patient's disease. Our research group focuses on developing functional precision medicine for B-cell malignancies, in particular chronic lymphocytic leukemia (CLL). By performing functional analyses such as drug sensitivity screening and single cell signaling analyses directly on the patients' cancer cells, our aim is to identify biomarker signatures that can predict treatment outcomes for the individual patient, and thus guide treatment decisions.
1. Skånland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, Tjønnfjord GE. Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechansims. An incex case. Haematologica, 2022, Online ahead of print.
2. Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. Mol Oncol, 2022, Mar;16(5):1153-1170.
3. Skånland SS and Mato AR. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia. Blood Advances, 2021, 5(1):334-343.
4. Skånland SS, Cremaschi A, Bendiksen H, Hermansen JU, Thimiri Govinda Raj DB, Munthe LA, Tjønnfjord GE, Taskén K.
An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL. Leukemia, 2020, 34(2):478-487.
5. Skånland SS. Phospho flow cytometry with fluorescent cell barcoding for single cell signaling analysis and biomarker discovery. J Vis Exp, 2018, 4(140):58386
Department of Cancer Immunology, Institute for Cancer Research
Oslo University Hospital, Ullernchausseen 70, 0379 Oslo, Norway